bioMerieux (OTCMKTS:BMXMF) Sees Large Drop in Short Interest

bioMerieux (OTCMKTS:BMXMF) saw a significant decline in short interest in the month of April. As of April 30th, there was short interest totaling 75,449 shares, a decline of 42.6% from the April 15th total of 131,417 shares. Based on an average trading volume of 260 shares, the short-interest ratio is presently 290.2 days. Approximately 0.1% of the shares of the company are sold short.

Analysts Set New Price Targets

Several brokerages recently issued reports on BMXMF. Zacks Research upgraded shares of bioMerieux to a “hold” rating in a research report on Tuesday, April 28th. BNP Paribas Exane lowered shares of bioMerieux to a “neutral” rating in a research report on Wednesday, January 28th. Finally, Deutsche Bank Aktiengesellschaft lowered shares of bioMerieux from a “buy” rating to a “hold” rating in a research report on Friday, April 24th. Three research analysts have rated the stock with a Hold rating, According to data from MarketBeat, the stock has a consensus rating of “Hold”.

bioMerieux Stock Performance

OTCMKTS:BMXMF opened at $84.00 on Monday. The stock has a 50-day simple moving average of $102.04 and a two-hundred day simple moving average of $115.25. bioMerieux has a 52-week low of $77.38 and a 52-week high of $152.00. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.39 and a quick ratio of 1.48.

About bioMerieux

bioMérieux is a global leader in in vitro diagnostics, specializing in the development, manufacture and distribution of diagnostic solutions that determine the source of disease and contamination to improve patient health and ensure consumer safety. The company’s product portfolio encompasses a broad range of assays and instruments for microbiological and immunoassay testing, including molecular diagnostics for infectious diseases, immunoassays for autoimmune and oncology markers, and traditional microbial identification and antimicrobial susceptibility testing.